Stem Cell Banking Market Size was valued at USD 5.1 billion in 2022. The Stem Cell Banking market industry is projected to grow from USD 5.87 Billion in 2023 to USD 18.08 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.10% during the forecast period (2023 - 2032).Growing rates of chronic illnesses and life-threatening genetic abnormalities are the key market drivers enhancing the market growth.
Â
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for stem cell banking is being driven by the rising awareness on the therapeutic potential. public awareness of the therapeutic potential of stem cells is growing as more clinical data is available. Furthermore, stem cells effectively treat over 80 diseases and conditions, including cancer, degenerative neuromuscular disorders, metabolic disorders, immune deficiency diseases, and hematological disorders. During the study period, it is anticipated that public awareness and the adoption of stem cell therapies and stem cell banking services will increase due to the continued rise in per capita disposable income in developing countries and an anticipated reduction in the costs of the products associated with these treatments. Cells, cell lines, and tissues are stored, collected, tested, and characterized in the cell banking outsourcing sector to ensure minimal side effects and maximum efficacy while producing R&D activities and biopharmaceuticals. But the exorbitant cost of maintaining these cells in cell banks is a big barrier for this industry. The sector is anticipated to be constrained by several legal concerns around stem cell banking and other forms of cell banking.
Careful cryopreservation of the cells is one step in establishing the cell bank. The three most important factors influencing the quality of cryopreservation are the biology of the cell line being frozen, the freezing medium being used, and the freezing or freeze profile technique. The cell bank size considerably influences the quality of cryopreservation since a smaller or larger bank may face more vial-to-vial variability due to temperature fluctuations, handling quirks, and timing variances. One of the key elements driving the market's expansion is the increased need for stem cell treatments. For preserving their biological characteristics, preventing contamination and deterioration, and enabling their effective use in fundamental and translational research and current and future therapeutic applications, stem cell applications in cell therapy, regenerative medicine, drug discovery, toxicity, and developmental biology research are very promising.
Furthermore, a lot of stem cells come from tissues that are one-time-only. For instance, once-discarded cord blood may treat various disorders like blood cancers. When needed, these cells, which have been routinely banked and stored for long periods, maybe utilized right away for therapy, and rapid treatment can stop the progression of the illness Thus, driving the Stem Cell Banking market revenue.
The Stem Cell Banking market segmentation, based on cell type, includes umbilical cord stem cells, adult stem cells, and embryonic stem cells. The embryonic stem cells segment dominated the market, accounting for 45% of market revenue. Because stem cells' potential uses in treatments and regenerative medicine are expanding. The wide range of blood and tissue cells that stem cells can renew and grow into makes them an effective study tool. The category is expected to rise due to rising demand for stem cell treatments and biologics and a growing emphasis on developing personalized medications. The growing emphasis on treating neurological illnesses also helps expand the market.
The Stem Cell Banking market segmentation, based on bank type, includes private banks, public banks, and hybrid banks. The private banks category generated the most income. Since they are kept for much longer, high-grade cryopreservation techniques and tools are used more frequently, boosting the segment's revenue base. Additionally, master cell banks are useful in various research and development areas related to gene and stem cell therapies.
Figure 1: Stem Cell Banking Market, by Bank Type, 2022 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Based on application, the Stem Cell Banking market segmentation includes thalassemia, cerebral palsy, diabetes, leukemia, and autism. The diabetes segment dominated the market. Patients with diabetes mellitus have much to gain from stem cell therapy. The phases of development and transcription factors involved in this process have been identified via research on the capacity of human embryonic stem cells to differentiate into islet cells. Diabetes can be treated using stem cells to stave off consequences like heart disease, blindness, renal failure, and amputation of limbs.
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Stem Cell Banking market will dominate this market due to the increasing manufacturing of vaccinations, therapeutic proteins, and antibiotics. The presence of several biopharmaceutical firms in the area has also fueled the rise of the cell banking outsourcing market in North America. Gene therapy can treat metabolic diseases, such as Parkinson's, Alzheimer's, and other malignancies, which are rising in incidence. The need for the region's cell banking outsourcing industry has increased due to this aspect.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: STEM CELL BANKING MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Stem Cell Banking market accounts for the second-largest market share. The need for cord blood banking will increase in the presence of activities carried out by the European Union and numerous organizations. Additionally, the growth of the regional stem cell banking market during the study period would be supported by uniform regulations implemented by the European government regarding the support of voluntary and free donations, procedures to standardize the testing of donated tissues and cells, and procedures to ensure document safety and traceability. Further, the German Stem Cell Banking market held the largest market share, and the UK Stem Cell Banking market was the fastest-growing market in the European region.
The Asia-Pacific Stem Cell Banking Market is expected to grow at the fastest CAGR from 2023 to 2032. the existence of pharmaceutical firms, who are putting Asia's sizable and largely untapped population as a top priority. High investments in the biotechnology industry and low cost of clinical trials are anticipated to drive this region's market expansion. Moreover, China's Stem Cell Banking market held the largest market share, and the Indian Stem Cell Banking market was the fastest-growing market in the Asia-Pacific region.
Stem Cell Banking Key Market Players & Competitive Insights
Leading market companies are spending a lot of money on R&D to diversify their product offerings, which will spur further growth in the stem cell banking industry. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The stem cell banking industry must provide affordable products to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies manufacturers employ in the stem cell banking industry to assist customers and expand the market sector is local manufacturing to reduce operating costs. The stem cell banking market has provided some in recent years. Some of the biggest benefits to medicine in recent years have come from the stem cell banking sector. Major competitors in the Stem Cell Banking market, such as Bayer and others, are investing in their research and development activities to boost market demand.
One of the biggest pharmaceutical businesses in the world is Bayer AG. Bayer AG is a German multinational pharmaceutical and biotechnology firm. In addition to medicines, Bayer sells consumer healthcare items, agricultural chemicals, seeds, and biotechnology goods. Bayer is based in Leverkusen. A part of the EURO STOXX 50 stock market index is the firm. In December 2020, As a result of their collaboration, Bayer and Atara Biotherapeutics have obtained the rights to two cell treatments that the latter has been developing for solid tumors, such as mesothelioma and non-small cell lung cancer. To begin the relationship, which will be focused on individualized cell therapy and an "off-the-shelf" treatment option, Bayer will pay Atara Biotherapeutics USD 60 million under the terms of the agreement.
American CryoStem Corporation, a licensor, a pioneer in autologous cellular processing and therapies, and American CryoStem Corporation (OTC PINK: CRYO), a biotechnology business in the clinical stages, is a pioneer in the processing and use of autologous cells in treatments. Through a single adipose-tissue (fat) harvest and ATCELL BankTM cryopreservation, the company's centralized laboratory model and proprietary "CryoStem Platform" provide a best-in-class, end-to-end cellular therapy solution to treat injuries, disorders, and chronic illnesses. The company develops customized adipose-derived mesenchymal stem cell therapies and provides as many genetically matched treatments as are required. In February 2021, American CryoStem Corporation clinical stage biotechnology company recently announced the signing of an agreement with FDA-registered umbilical cord tissue manufacturer BioTherapeutic Labs Corp. (BTL).
Key Companies in the Stem Cell Banking market include
CBR Systems, Inc. (US)
Cryo-Cell International, Inc. (US)
Cordlife (Singapore)
Cryo-Save AG (Netherlands)
Cord Blood Corporation (Hong Kong)
Americord Registry LLC (US)
Smart Cells International Ltd. (UK)
Celgene Corporation (US)
BrainStorm Cell Therapeutics (US)
Regrow Biosciences Pvt. Ltd. (India).
Stem Cell Banking Industry Developments
April 2021:Due to a spike in demand brought on by the COVID-19 pandemic, LifeCell International, a pioneer and industry leader in stem cell banking, announced intentions to enhance its diagnostics and biologics business divisions. LifeCell's biologics division has unveiled several products made from placental tissue that has been dried and sterilized for use in advanced wound care.
April 2021:Beginning in April 2021, patients needing bone marrow transplants will have access to cord blood thanks to a partnership between the SA Bone Marrow Registry (SABMR) and Netcells, the continent's oldest private cord blood bank. The deputy director of SABMR claims that having access to cord blood will greatly aid the registry in finding the right matches, particularly for patients of ethnic backgrounds.
Umbilical Cord Stem Cells
Adult Stem Cells
Embryonic Stem Cells
Private Banks
Public Banks
Hybrid Banks
Thalassemia
Cerebral Palsy
Diabetes
Leukemia
Autism
Stem Cell Banking Regional Outlook
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 5.1 billion |
| Market Size 2023 | USD 5.87 billion |
| Market Size 2032 | USD 18.08 billion |
| Compound Annual Growth Rate (CAGR) | 15.10% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Cell Type, Bank type, Application and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | CBR Systems, Inc. (US), Cryo-Cell International, Inc. (US), Cordlife (Singapore), Cryo-Save AG (Netherlands), Cord Blood Corporation (Hong Kong), Americord Registry LLC (US), Smart Cells International Ltd. (UK), Celgene Corporation (US), BrainStorm Cell Therapeutics (US), Regrow Biosciences Pvt. Ltd. (India) |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Dynamics | Worldwide surging newborn population Growing awareness about stem cell therapeutics |
Stem Cell Banking Market Highlights:
Frequently Asked Questions (FAQ) :
The Stem Cell Banking market size was valued at USD 5.1 Billion in 2022.
The market is projected to grow at a CAGR of 15.10% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are CBR Systems, Inc. (US), Cryo-Cell International, Inc. (US), Cordlife (Singapore), Cryo-Save AG (Netherlands), Cord Blood Corporation (Hong Kong), Americord Registry LLC (US).
The private bank category dominated the market in 2022.
The Diabetes had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
